OncoMatch

OncoMatch/Clinical Trials/NCT02297217

Chemoradiotherapy for Advanced Esophageal Cancer

Is NCT02297217 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Carboplatin and Taxol (paclitaxel) for esophageal cancer.

Phase 2RecruitingAHS Cancer Control AlbertaNCT02297217Data as of Jun 2026Location: Canada

Treatment: Carboplatin and Taxol (paclitaxel)This study aims to show that the addition of carboplatin and paclitaxel chemotherapy to a palliative course of external beam radiation treatment improves both dysphagia relief and patient quality of life in patients with unresectable esophageal cancer.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Chemotherapy

Carboplatin and Taxol (paclitaxel)

Cancer type

Esophageal Carcinoma

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: radiation therapy

Previous radiotherapy delivered to the chest.

Cannot have received: cytotoxic chemotherapy

Previous chemotherapy for esophageal cancer

Lab requirements

Blood counts

Hemoglobin > 100g/L; Platelet count > 100x10E9/L; Absolute neutrophil count > 1.5x10E9/L

Kidney function

Calculated creatinine clearance ≥ 50 mL/min using the Cockcroft-Gault formula

Liver function

AST and ALT ≤ 2.5x ULN (≤ 5 if liver metastases); total bilirubin ≤ 1.5x ULN

Hematological function as defined by the following laboratory parameters: Hemoglobin > 100g/L; Platelet count > 100x10E9/L; Absolute neutrophil count > 1.5x10E9/L. Renal function to undergo chemotherapy as defined by the following laboratory parameters: AST and ALT ≤ 2.5x ULN (≤ 5 if liver metastases); total bilirubin ≤ 1.5x ULN; Calculated creatinine clearance ≥ 50 mL/min using the Cockcroft-Gault formula

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT02297217 currently recruiting?

Yes, this trial is currently recruiting patients.

Can patients have received prior systemic therapy?

No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify